Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc. (NASDAQ: XENE) is a neuroscience-focused biopharmaceutical company dedicated to the discovery, clinical development, and commercialization of innovative therapeutics for patients with neurological and psychiatric disorders. The company's website is www.xenonpharma.com.

The company's pipeline is led by azetukalner, a novel potassium channel opener in late-stage clinical development for multiple indications. Azetukalner is being evaluated in Phase 3 studies for focal onset seizures and primary generalized tonic-clonic seizures in epilepsy, as well as for major depressive disorder and bipolar depression. The company's Phase 2b X-TOLE study demonstrated that azetukalner achieved statistically significant reductions in monthly focal seizure frequency across all tested doses compared to placebo, with the 25 mg dose showing a median 52.8% reduction. The company's early-stage pipeline includes next-generation ion channel modulators targeting Kv7 potassium channels and Nav sodium channels for pain and other neurological indications, including programs for Dravet syndrome and acute pain.

Xenon's business strategy centers on leveraging its discovery capabilities, which are founded on understanding channelopathies combined with proprietary biology and medicinal chemistry assets. The company pursues a combination of internal development and selective collaborations to expand its capabilities and commercial opportunities. A significant partnership with Neurocrine Biosciences, established in December 2019, involves the development of sodium channel inhibitors, with NBI-921355 progressing into Phase 1 clinical studies.

The company maintains a comprehensive intellectual property portfolio with eight U.S. issued patents and 36 foreign issued patents specifically covering azetukalner, with patent protection expected through 2046. Xenon also holds intellectual property related to selective Nav inhibitors and other ion channel programs. As an accelerated filer with the Securities and Exchange Commission, the company is subject to standard public company reporting requirements and maintains internal controls over financial reporting.